Geron Corporation (Nasdaq: GERN), a biopharmaceutical leader focused on transforming the treatment of blood cancers, announced today the appointment of Joseph Eid, M.D., as Executive Vice President of Research and…
Cyrus Biotechnology, Inc., a Seattle-based biotech company leveraging a novel hybrid AI/screening platform for biologics discovery, will showcase its expertise in protein engineering and risk mitigation for therapeutics at the…
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing innovative logic-gated cell therapies to selectively target tumor cells while sparing normal cells, today presented updates on its Tmod™…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced that on November 8, 2024, its Compensation Committee granted inducement awards to seven new employees under the company’s 2020 Inducement Plan. These awards consist…
Palleon Pharmaceuticals, a clinical-stage company leading innovation in glyco-immunology for autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602. This first-in-class human sialidase enzyme…
GE HealthCare Technologies Inc. (Nasdaq: GEHC) announced today the launch of a secondary underwritten public offering of 13,281,302 shares of its common stock (the “GEHC Shares”). The company is not…
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay”) announced today that it has accepted a revised offer from PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to raise the base purchase price for…
MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech leader in developing microbiome-based therapies for cancer, today provided an update on its activities and financial performance for the third quarter of 2024,…
Genmab A/S (Nasdaq: GMAB) today announced that over 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a subcutaneously administered T-cell engaging bispecific antibody, will be presented at the 66th Annual Meeting of the…
Immunis, Inc., a clinical-stage biotechnology company focused on developing innovative secretomes for age-related diseases and immune dysfunction, has launched non-terminal safety studies for canine muscle atrophy in collaboration with VetBio…
BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System for treating urge urinary incontinence (UUI), announced that the Centers for Medicare & Medicaid…
Biomodal, an omics-based life sciences technology and analytics company, announced today that it will present new data showcasing the effectiveness of its duet multiomics solution, evoC, in the early detection…